1. Introduction
Inborn errors of metabolism (IEM) constitute a significant group of rare genetic diseases affecting individuals of all ethnicities and ages [1]. IEM genetic variants are rare in the population, and children with these disorders exhibit a high morbidity risk, including intellectual and motor disability and premature mortality [2,3,4].
Inborn errors of intermediary metabolism (IEiM) are a subgroup of IEM comprising numerous conditions related to catabolism, anabolism, energy use, storage, and generation. IEiM affects thousands of proteins, mainly enzymes or transporters [5,6]. Many of these diseases are treatable with different approaches, such as dietary, pharmacological, enzyme replacement, and surgical (liver and liver–kidney transplant) therapies; gene replacement therapies will soon be available [7,8].
A significant number of IEiMs are associated with well-known biomarkers (amino acids, acylcarnitines, succinylacetone, or organic acids) that can be quantified in biological fluids, i.e., blood and urine, using robust methodologies, such as tandem mass spectrometry (MS/MS), high-performance liquid chromatography (HPLC), or gas-chromatography–mass-spectrometry (GC-MS) [9,10]. The quantification of these biomarkers has allowed the diagnosis of symptomatic patients (high-risk screening) and forms the basis for presymptomatic expanded newborn screening (NBS) programs [11]. Unfortunately, NBS programs that include the detection of IEiM by MS/MS still need to be universal. Latin American patients affected by these disorders have been largely under-represented in worldwide studies due to, among other reasons, a lack of awareness of these disorders among health personnel, leading to an underdiagnosis. Additionally, Latin American NBS programs are limited to the detection of only a few diseases [12] and have limited access to metabolic and genetic tests, such as Sanger sequencing, whole exome sequencing (WES), and whole genome sequencing (WGS) [13,14]. In Mexico, the mandatory NBS panel of the Ministry of Health, which attends most of the births in Mexico, comprises only six diseases: congenital hypothyroidism, phenylketonuria (HPA/PKU), congenital adrenal hyperplasia, galactosemia (GALAC), cystic fibrosis, and glucose-6-phosphate dehydrogenase deficiency [15]. In addition, there is a large variability in the NBS panels between the institutions constituting the national health system [16].
Although rare diseases indiscriminately impact all socioeconomic, geographic, and ethnic groups [17], advances in genetics, including diagnoses, epidemiology, molecular spectrum, management, therapies, and efficient NBS programs, have been established predominantly in high-income countries with populations of European ancestry, mainly because the study of patients with rare disorders requires infrastructure, permanent financial funding, extensive expertise, and public health policies [18,19].
Few works have been published on the epidemiology of IEiM in Mexico, and most cover regional or local experiences regarding specific disorders [20,21,22,23,24,25,26,27,28]. Therefore, Mexican patients with IEiM are under-represented in the current literature. In this observational study at our national reference center with 33 years of experience, we overviewed the epidemiological characteristics of a historical cohort of Mexican patients, emphasizing the disease frequency, geographical distribution, gaps in diagnoses and treatment, unmet diagnostic needs, diagnostic odyssey, and difficulties in traveling to the center among the included patients.
2. Methods
2.1. Study Design
We conducted a retrospective observational study of a historical cohort of patients with IEiM.
2.2. Setting Location
A clinic devoted to the medical care of patients with IEiM was established in 1990 at the National Institute of Pediatrics (INP, by its abbreviation in Spanish) in Mexico City, a high-specialty government public institution dependent on the Ministry of Health.
2.3. Period of Data Collection
The patient files were reviewed, and their date of birth, geographical origin, sex, age at symptom onset, disorder name, and disorder mode of inheritance were obtained.
The studied cohort comprised patients diagnosed in our center or patients whose IEiM diagnosis was established in other medical units, who were referred to our center for continuity of treatment (hereafter described as “referred”).
Patients were categorized as follows: (1) screened (those with positive NBS results performed at any health facility) and (2) unscreened (those sick children clinically suspected of having IEiM who were hospitalized or ambulatory). In this category, the older unscreened affected siblings were also included.
2.4. Case Definition, Confirmation, and Disorder Classification
Diagnostic biochemical confirmatory studies were performed in our center using MS/MS, GC-MS, HPLC, fluorometry, and orotic acid quantification, among other methods, as previously described [29]. Cases were classified as definitive as described by Sontang et al. according to the biochemical results (i.e., the presence of alloisoleucine for maple syrup urine disease (MSUD) cases or elevated Phenylalanine (Phe); diminished tyrosine (Tyr) and a Phe/Tyr ratio > 2 for hyperphenylalaninemia/phenylketonuria (HPA/PKU) cases) [30,31].
The number of patients accessing genetic testing to identify their pathogenic variants and the methodologies used (e.g., Sanger and exome sequencing) were recorded. The funding source for the genetic test (i.e., our governmental institution or other public or private institutions) was also registered. As this study comprised data across 33 years, assuming that advances in genetic testing were different in 1990 compared with the present time, we separated access to genetic testing into three periods: 1990 to 2000, 2001 to 2010, and 2011 to 2022.
2.5. Disorder Classification
The different detected IEiM were classified as amino acid metabolism, organic acid, urea cycle, defects of carbohydrate metabolism, lipid metabolism, mitochondrial fatty acid oxidation and related metabolic pathway, vitamin-responsive, and amino acid transport disorders. Their International Classification Disorders Classification 11th Revision of the IEiMs was included. Also, the amenability of each disease to expanded NBS was assessed based on the U.S. recommended uniform newborn screening panel (RUSP) information [31], as well as the existence of currently accepted treatments for each disorder and their availability in Mexico being assessed. NBS critical disorders were also registered. Critical disorders are IEMs that may present acutely in the first weeks of life and require immediate treatment to mitigate morbidity and mortality [32].
2.6. Diagnostic Delay, Travel from Habitual Address to Our Reference Center, and Mortality Rates
The diagnostic delay (the time between symptom onset age and the age at diagnosis), the number of other affected siblings in the family, and if death occurred were analyzed. The distance in km from the habitual residence of the patients to the metabolic clinic located in Mexico City was also determined and compared with the proportion of patients with other diseases who routinely come to our institution for medical care (such as cancer, neurosurgery, urology, and nephrology). The distance patients had to travel from their habitual residence place to our institution to have a diagnosis made and obtain treatment was recorded.
Mortality by disease was also assessed for all illnesses. An analysis excluding conditions with the same mortality rate as that observed in the general population, such as HPA/PKU or 3-methylcronyl-CoA carboxylase deficiency (MCC) [33,34], was performed to avoid bias. Kaplan‒Meier survival curves were generated for disorders with the highest mortality rates.
2.7. Statistical Methods
Statistical analyses were performed with GraphPad Prism version 9.2. Medians with IQR1 and IQR3 (minimum and maximum) were used for the statistical description of the cohort. Where necessary, a comparison of proportions was performed. Missing data were addressed by adjusting the “n” number where applicable.
2.8. Ethical Considerations
This study is part of research project number 2022/051, approved by the National Institute of Pediatrics Research, Ethics and Biosafety committees, and was performed according to the guidelines of the Helsinki Declaration.
3. Results
Data from 924 patients with IEiM were studied; 445 (48.16%) females and 479 (51.84%) males were analyzed. The data comprised 835 Mexican families, of which 79 had more than one affected child (74 had two affected siblings, 4 had three, and 1 had eight). The older siblings were affected in 39/79 (49.36%) families, and the diagnosis was confirmed as part of the family history. Only one multiple pregnancy (twins) was registered. Consanguinity was documented in 13.5% of the families, and 35/100 (35%) of these families had access to expanded NBS.
We found 40 different IEiMs, and according to the affected metabolic pathway, the most frequent disorders were aminoacidopathies, followed by organic acid disorders (Figure 1).
In Figure 2, a general diagram of the study is presented, showing the number of disorders found and classified by those detectable or not detectable by NBS. Twenty-nine IEiMs were detectable by NBS. The highest number of screened patients were categorized with HPA/PKU (49.3%), followed by galactosemia (GALAC) with 16.8%.
The detected diseases and their respective number of patients are shown in Table 1. The most frequent disorder found was HPA/PKU, which represented 195/924 (21.1%) cases, followed by MMA, which represented 119/924 (12.9%) patients.
An average of 28 new cases arose per year, with the 5 most frequent being HPA/PKU, methylmalonic acidemia (MMA), MSUD, GALAC, and propionic acidemia (PA) (Figure 3).
The patients came from all 32 states of the Mexican Republic. The overall geographical distribution of cases as well as that of the five more frequently diagnosed disorders are shown in Figure 4. Detailed information on the remaining diseases is shown in Table S1. Remarkably, 80% of the patients had to travel long distances to arrive at our metabolic center; the longest was 2300 km (Table 2).
In the unscreened group, when data on symptom onset and age at diagnosis were available, the diagnostic delay was calculated (n = 376 patients), and the results are shown in Figure 5. Homocystinuria (HCY) had the highest diagnostic delay, with a median of 5.2 years, followed by 3-methylglutaconic aciduria (3MGA), with a median diagnostic delay of 2.9 years.
Excluding the referred patients and those whose disease is not detectable with NBS, we analyzed the differences in age at arrival, mortality percentage, and access to genetic tests between screened and unscreened patients diagnosed at our center (Table 3). The median age at arrival at our metabolic center was significantly lower for the screened group (1.5 months) than for the unscreened group (10.1 months), p < 0.0001. To avoid bias, we analyzed overall mortality and mortality, excluding diseases with the same mortality rate as the general population (i.e., HPA/PKU and MCC) and those disorders not detectable by NBS. The adjusted percentage of dead patients was higher in the unscreened group (Table 3). Remarkably, the mortality in the unscreened patients was over two-fold higher than that in the screened group (p < 0.0001). Kaplan–Meier survival curves of the five disorders with the most increased mortality percentage are shown in Figure 6. It can be observed that a 50% survival probability was at 3 and 6 months for patients with MMA and MSUD, respectively.
Table S2 presents detailed information on patients who underwent genetic testing organized by disease. Only 309/924 (33.4%) patients had access to genetic testing; in 236/309 (76.3%), the genotype was established with Sanger sequencing at our institution, and the remaining 73/309 (23.6%) tests were performed at other private or public institutions with Sanger sequencing or WES. The type of funding used for the genetic test was also considered. The genetic studies conducted at our institution were financed through research protocols; on other occasions, these studies were paid for by the families or a private sponsor, such as a pharmaceutical company. Additionally, access to genetic testing by period was null in the 1996–2000 period, and in the 2001–2010 decade, only 39 patients (4.2% of the analyzed population) underwent genetic testing. From 2011 to 2023, 270 patients (29.2% of the analyzed population) received genetic testing.
The treatments currently described in the literature for the 40 disorders found in this study include nutritional restriction treatment, cofactor supplementation, pharmacological therapy (nitisinone, cysteamine, sapropterin, and carglumic acid), enzyme replacement therapy, and liver or liver–kidney transplantation; most of these treatments are available in Mexico (Table S3).
4. Discussion
Herein, we present the disparities and unmet needs identified in a cohort of Mexican patients with IEiM to achieve an accurate and prompt diagnosis. To our knowledge, this study involves the largest cohort of patients with IEiM described in Mexico in the last 33 years. Regarding the spectrum of IEiM, amino acid disorders and organic acidemias were the most frequent IEiMs (Figure 1), which coincides with previous reports from others worldwide [35,36]. We found that 30/40 (75%) disorders were detectable by expanded NBS and treatment [1,31]. Unfortunately, the most striking disparity was that only 35.4% (293/828) of the patients had access to expanded NBS (Figure 2).
As demonstrated in Figure 4, the geographical distribution of the studied IEiM is variable, showing some clusters. For HPA/PKU, the high prevalence in the central west part of the country has been associated by our group with a founder effect [37,38]. Still, the apparent presence of clusters for other diseases, i.e., PA in the Mexico City area or MSUD in the Pacific area, has yet to be explored and deserves more studies due to the lack of epidemiological data. Additionally, the cluster observed in Tabasco could be due to a pilot expanded NBS program that was performed in that state.
In this study, we observed only seven MCAD cases. This is notably lower from those reported in other populations, mainly Caucasian, where MCAD is one of the most frequent IEiMs [39,40]. Feuchtbam et al., in 2012, reported the birth prevalence of several disorders detectable through NBS by race and ethnicity in California, US, analyzing more than two million newborns [41]. One of the most interesting findings of Feuchtbam et al. is that in the “Hispanic” group, the prevalence of MCAD was notably lower (4.5 per 100,000 newborns) than in Native Americans (13.4 per 100,000 newborns) and Whites (9.4 per 100,000 newborns). Another fact that could explain our findings is that some FAOD, including MCAD, could be undetected due to neonatal or childhood sudden death without a diagnosis. This points out the necessity to perform well-planned NBS pilot programs. Further studies about MCAD birth prevalence are needed in Mexico, especially considering that several authors have demonstrated that expanded NBS for MCAD is cost-effective and could save fatal outcomes in nearly one of seven patients, with low-cost treatment measures (frequently feeding to avoid fasting) [42,43].
Despite Mexico’s NBS program being the first implemented in Latin America [12], it has faced many obstacles and challenges not yet resolved that require urgent modernization. One of the main obstacles NBS programs have met in Mexico is the health system’s complexity, characterized by considerable fragmentation, giving the different population groups unequal access to public resources and other health benefits [44]. Mexico has as many NBS panels as existent health institutions performing screening [16]. Our center is part of the Mexican Ministry of Health, where the mandatory NBS panel includes the detection of only two IEiMs (HPA/PKU and GALAC) and four other diseases (congenital hypothyroidism, congenital adrenal hyperplasia, cystic fibrosis, and glucose-6-phosphate dehydrogenase deficiency) [15]. A possible effect of this mandatory panel could be supported by the fact that in our studied cohort, the two disorders with the highest percentages of screened patients were HPA/PKU (49.3%) and GALAC (16.8%). Nevertheless, the rate of screened patients remains significantly unsatisfactory, given that the targeted coverage for NBS is expected to be 100% [45]. Thus, our patients with IEiM detectable by NBS are frequently detected late.
On the other hand, within the Mexican private healthcare system, the provision of childbirth or cesarean section care is bundled into a comprehensive “package”, which encompasses the expanded NBS and is administered by various healthcare providers. Regrettably, a significant deficiency exists within most private hospitals in our nation, characterized by the absence of systematic follow-up mechanisms for NBS. Consequently, families receiving positive NBS results must request confirmation and treatment at our institution. In other instances, NBS procedures have been conducted in foreign countries, primarily the United States. Owing to the irregular immigration status of these families, they find themselves obliged to return to Mexico, where they seek medical care for their infants.
The benefits of expanded NBS have been profusely documented, with an early diagnosis, early treatment, and a favorable cost–benefit relationship [46,47]. The disparity observed in our population must be corrected, especially considering that the number of patients arriving at our institution has increased over time (Figure 3). Furthermore, due to the lack of expanded NBS for IEiM in Mexico, this work demonstrates that most patients experienced a long diagnostic delay (Figure 5). This is especially relevant for certain IEiM, considered a critical disorder due to its devastating natural history, where the diagnosis must be performed in the first days of life [32].
As it is known, most of the IEiMs are inherited in an autosomal recessive manner, and the risk of an affected product is 25%. In our study, we documented the presence of other affected members in 79 families. This fact emphasizes the importance of obtaining a complete family history in all patients. Performing biochemical or genetic studies on older siblings must be mandatory since affected siblings should receive treatment and follow up, regardless of age. Furthermore, families with an affected IEM child must receive professional genetic counseling, especially considering future pregnancies [29]. The consanguinity rate in this study (13.5%) was noticeably lower than the overall consanguinity meta-analysis estimated at 51.47% by Waters et al., for IEiM worldwide [3], but is higher than the 1–4% previously reported in Mexico [48].
The adjusted mortality observed in this study was significantly higher in the unscreened patients (26.8%) than in the screened patients (14.58%) (Table 3). The highest mortality rate was observed in diseases such as MMA, PA, MSUD, and ornithine transcarbamylase deficiency (OTC) (Figure 6), all of which are detectable by expanded NBS [31]. High mortality for those diseases has also been observed in other cohorts of patients, regardless of the type of diagnosis mode and treatment [49,50,51].
Of the 40 IEiMs detected in the studied patients, thirty-five (87.5%) have a therapy available in Mexico (Table S3). Since one of the inclusion criteria for disorders to be screened is that they have an available treatment [31], the fact that 87.5% of IEiM disorders found are treatable [52,53,54] gives more support for their inclusion in the NBS mandatory panel in the Mexican Ministry of Health.
Other findings are worth mentioning. The survival probability of patients with some diseases, such as tyrosinemia type 1 (TYR-1), has increased mainly due to the combination of expanded NBS with the availability of early pharmacological therapy (nitisinone) and liver transplantation [24] (Figure 6E).
Another advance is the continuous growth of the overall number of cases at our reference center, with an average of 28 patients per year (Figure 3). The evolution of our technological platform could explain this, mainly the implementation of MS/MS in 2010 and the consolidation of a specialized interdisciplinary team composed of metabolic pediatricians, dietitians, biochemists, geneticists, and other professionals, such as quality-of-life experts. This team exerts joint efforts to increase the knowledge and awareness of health personnel to promote continuous training and diffusion of knowledge about NBS throughout the country [20,21,22,23,26,27,28,55,56,57]. Another reason could be the increase in private laboratories, including the expanded NBS service following the U.S. RUSP panel [12,31]. The observed maximum peak of 56 cases in 2014 could be related to the pilot programs of the NBS for HPA/PKU and GALAC in Mexico and its later inclusion in the national mandatory NBS panel [15]. We observed a critical decline in the number of cases in 2020 and 2021; this could be explained with the COVID-19 pandemic, which affected the number of diagnosed cases reported in other populations of IEM patients [58,59], as well as with the diversion of financial healthcare resources for attending the more significant needs of the COVID-19 pandemic. Another reason could be the decrease in registered births in the 2020 year, where they decreased from 2,092,214 in 2020 to 1,629,211 in 2021 (INEGI,
NBS panel selection is a complex public health issue, and the addition of diseases must be performed carefully, considering many factors, such as the benefits, the possible harms, and the economic factors, among others [60,61,62]. In addition, controversies still exist for conditions like 3MCC, which are generally asymptomatic [63], and have even been removed from some NBS programs [64]. MET is also debatable due to its benign clinical course [65]. In our study, we found nine individuals with 3-MCC who did not have NBS; eight of them were siblings of a patient detected by NBS who were asymptomatic. The ninth patient was a 4-year-old child without NBS who presented a metabolic crisis characterized by vomiting, feeding refusal, metabolic acidosis, and seizures, so she was admitted to the emergency department in our institution. In this patient, as part of the metabolic acidosis study protocol, we performed the GCMS study, which showed the characteristic profile of organic acids of 3MCC. We also have another symptomatic 3MCC patient detected by NBS who developed hyperammonemia crises at 6 months, which deserved hospitalization and medical management in the emergency room, with good outcomes. These results show weak evidence supporting whether 3MCC must be deleted or not from NBS programs.
Another concern about the obsolesce of the NBS program of the Mexican Ministry of Health is that while we keep searching for the expansion of the program to detect IEiMs by MS/MS, currently developed countries are already exploring genomic NBS with WES or even WGS techniques [66]. If this gap is not overcome, it will further deepen the inequities in access to NBS between different regions worldwide. Genetic studies are essential for the adequate diagnosis, management (i.e., selection of patients for specific treatment), and prognosis of IEiM patients, especially in the pediatric population and even more so in critically ill patients, allowing personalized medicine approaches [67,68]. These studies are also helpful for the establishment of the prognosis of those cases of MAA where different forms (mut0 and mut-) of the disease differently impact the patient survival [69,70].
Furthermore, genetic sequencing could be an alternative for diagnosing IEiMs without a specific diagnostic biomarker [71].
Unfortunately, only 309/924 (33.4%) patients had access to molecular studies, and the molecular studies were only performed for 30/40 (75%) disorders; this information is detailed in Table S2. Most genetic studies of the patients reported herein were performed in the last decade (270/309, 87.4%). This increase in testing coincides with the growing technological advances in DNA sequencing that began in the 1990s and have expanded in recent years [72]. WGS and WES sequencing techniques have demonstrated usefulness [73,74] and advantages over Sanger sequencing. The Sanger technique has limitations in that it is time-consuming and can only analyze one gene at a time [75], but it is still valuable for confirmation of findings on clinical exome sequencing.
At our institution, Sanger sequencing is the only methodology available for genotyping [75]. This is the main reason why we have only performed the genetic studies of six groups of conditions (HPA/PKU [27], TYR-1 [76], GALAC [20], tetrahydrobiopterin defects (BH4D) [28], cystinosis (CTNS) [22], and MMA [21]) at our center and only under research protocols, not as permanently available routine tests (Table S2); thus, molecular studies of the patients were not always performed at the same time of their arrival to our institution. Technological modernization and investment in adequate genotyping methods are needed to fill this gap. A systematized public health program and budget for sequencing large numbers of patients would expedite IEiM diagnoses, especially for those associated with more than one gene (i.e., PA, MSUD, or MMA) or without specific biomarkers for a biochemical diagnosis such as glycogen storage disease (GSD). As other authors have demonstrated, it is necessary to improve access to WES or WGS in this group of patients [77,78,79].
5. Conclusions
Our study underscores the critical need for a comprehensive and up-to-date newborn screening (NBS) program in Mexico to address the unmet needs and disparities faced by patients with rare diseases, including IEiMs. Establishing regional medical care centers and implementing public health policies aimed at raising awareness and promoting the early diagnosis and management of these disorders is crucial. Our findings provide compelling evidence that could prove valuable to decision makers overseeing public health initiatives for individuals impacted by IEiMs in middle- and low-income countries.
It is essential to prioritize and allocate resources to develop and implement a well-planned, sustainable, and expanded NBS program for early detection and prompt management of IEiM in Mexico, Latin America, and other middle- and low-income countries. Furthermore, implementing an updated and expanded NBS program can provide valuable insights into the prevalence and distribution of IEiMs and other rare diseases in these countries, which can inform future research and clinical practice. Ultimately, the successful implementation of a comprehensive and sustainable NBS program can significantly impact the health and well-being of individuals and communities affected by these devastating disorders, and it is an urgent public health priority in Mexico and other middle- and low-income countries. Implementing such programs will reduce the burden of IEiM morbidity and mortality on individuals, families, and healthcare systems, leading to better health outcomes and improved quality of life.
It is also important to remark on the necessity of national experts’ consensus who, following the existent scientific evidence and ethical criteria, determine the best NBS panel for Mexico.
Beyond the implementation of comprehensive and sustainable NBS programs is the need for access to permanent treatment for detected patients, along with systematized national algorithms for the massive DNA sequencing of patients to confirm their diseases and to personalize medical care. The establishment of permanent training of health personnel for rare diseases throughout the country is also urgently needed.
I.I.-G., C.F.-L. and M.V.-A.: Conceptualization, Methodology, Investigation, Formal analysis, Software, Writing—original draft. L.B.-M., S.G.-L., L.L.-M., R.I.C.-N. and N.A.G.-Z.: Methodology, Writing—review and editing. M.V.-A.: Writing—review and editing, Supervision, Project administration. All authors have read and agreed to the published version of the manuscript.
As stated in the Methods sections, this study was approved by the Ethics, Biosafety, and Research committees of the National Institute of Pediatrics (research project number 2022/051).
Written informed consent was obtained from families.
The original contributions presented in the study are included in the article; further inquiries can be directed to the corresponding author.
We thank the patients and their families for their support and commitment. The authors gratefully acknowledge Chemist Aída Jannete Hernández Montiel, technicians Luis Ricardo Morales González and Jaime Torres Marcial for their technical assistance, and bachelor’s in medicine students André Astudillo Trejo and Daniela Mancera Hernández.
The authors declare no conflict of interest.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Enlarge this image.Figure 1. Frequency of inborn errors of intermediary metabolism in the studied population at a Mexican reference center, categorized according to the affected metabolic pathways.
Enlarge this image.Figure 2. General scheme of the study. The IEiMs found are divided by their detectability or non-detectability through NBS. The group of screened patients is detailed by disease and proportion. Abbreviations. PA, propionic acidemia; TYR-1, tyrosinemia type 1; EE, ethylmalonic encephalopathy.
Enlarge this image.Figure 3. Number of new inborn errors of intermediary metabolism cases detected per year, presented in total (40 disorders), and for the 5 most frequent diseases.
Enlarge this image.Figure 4. Geographical origin of patients with inborn errors of intermediary metabolism in Mexico, presented in total and for the five more frequently detected disorders.
Enlarge this image.Figure 5. Median of the diagnostic delay of unscreened patients with inborn errors of intermediary metabolism (n = 376 patients); 1 month = Limit for early diagnosis time in screened patients.
Enlarge this image.Figure 6. (A–E) Kaplan‒Meier survival curves of the patients with inborn errors of intermediary metabolism with the highest mortality rates.
Inborn errors of intermediary metabolism detected, number of patients, and their classification according to the detection mode (screened, unscreened, and referred).
| Detected in Our Center | Referred from Other Centers ** | ||||||
|---|---|---|---|---|---|---|---|
| n = 727 | n = 197 | ||||||
| Screened | Unscreened | Screened | Unscreened | Total Number of Patients | Gene | ICD-11 * | |
| n = 162 (22.3%) | n = 565 (77.7%) | n = 131 (66.4%) | n = 66 (33.5%) | n = 924 | |||
| Detectable by NBS (amino acids, acylcarnitines and succinylacetone) | |||||||
| Hyperphenylalaninemia/Phenylketonuria (HPA/PKU) | 92 | 43 | 52 | 8 | 195 | PAH | 5C50.00 |
| Methylmalonic aciduria (MMA) | 6 | 99 | 3 | 11 | 119 | MUT, MMAA, MMAB, MMACHC, MMADHC, MTRR, LMBRD1, MTR, ABCD4, MCEE, SUCLG1, SUCLA2, ACSF3 | 5C50.E |
| Maple syrup urine disease (MSUD) | 5 | 67 | 1 | 7 | 80 | BCKDHB, BCKDHA, DBT | 5C50.D0 |
| Galactosemia (GALAC) | 1 | 23 | 48 | 7 | 79 | GALT | 5C51.4 |
| Propionic acidemia (PA) | 1 | 37 | 6 | 44 | PCCB, PCCA | 5C50.E0 | |
| 3-Methylcrotonyl-CoA carboxylase 1 deficiency (MCC) | 21 | 9 | 7 | 37 | MCCC1 | 5C50.DY | |
| Isovaleric acidemia (IVA) | 2 | 24 | 1 | 6 | 33 | IVD | 5C50.DY |
| Homocystinaemia (HCY) | 24 | 3 | 27 | CBS | 5C50.B | ||
| Fatty acid oxidation disorders (FAOD) | 7 | 17 | 2 | 1 | 27 | SLC22A5, CPT1, SLC22A5, SLC25A20, SLC25A20, CPT2, ACADVL, ACADM, ACADS, ACAD9, ECHS1, HADHA, HADHB, HADHSC, NADK2, MECR, ETFA, ETFB, ETFDH | 5C52.0 |
| Citrullinemia (CIT-1) | 5 | 15 | 2 | 3 | 25 | ASS1 | 5C50.A3 |
| Tyrosinemia Type I (TYR-1) | 1 | 23 | 1 | 25 | FAH | 5C50.11 | |
| Argininemia (ARG) | 4 | 17 | 2 | 23 | ARG1 | 5C50.A2 | |
| Tetrahydrobiopterin deficiencies (BH4D) | 3 | 14 | 1 | 1 | 19 | PTS, QDPR, PCBD1 | 5C50.0Y/5C59 |
| Glutaric acidemia type 1 (GA) | 2 | 12 | 1 | 2 | 17 | GCDH | 5C50.E |
| 3-hydroxy-3-methylglutaric aciduria (HMG) | 3 | 12 | 1 | 16 | HMGCL | 5C52.02 | |
| Biotinidase deficiency (BTD) | 2 | 1 | 7 | 1 | 11 | BTD | 5C50.E0 |
| Multiple carboxylase deficiency (MCD) | 9 | 9 | HLCS | 5C50.E | |||
| Beta-ketothiolase deficiency (BKT) | 8 | 8 | ACAT1 | 5C50.DY | |||
| Argininosuccinic aciduria (ASA) | 1 | 4 | 1 | 1 | 7 | ASL | 5C50.A0 |
| Hypermethioninemia, isolated persistent (MET) | 5 | 1 | 6 | MAT1A | EC50.B | ||
| 2-methyl-3-hydroxybutyryl Co-A dehydrogenase deficiency (MHDB) | 3 | 3 | HSD17B10 | 5C52.01 | |||
| 3-Methylglutaconic aciduria (3MGA) | 3 | 3 | AUH | 5C50.DY | |||
| Ethylmalonic encephalopathy (EE) | 1 | 2 | 3 | ETHE1 | 5C50.E | ||
| Glycine encephalopathy (GE) | 3 | 3 | AMT, GLDC, GCSH | 5C50.70 | |||
| Gyrate atrophy of choroid and retina (GACR) | 3 | 3 | OAT | 5C50.9 | |||
| Succinyl CoA:3-oxoacid CoA transferase deficiency (SCOT) | 2 | 2 | OXCT1 | 5C52.02 | |||
| Tyrosinemia type 3 (TYRSN3) | 2 | 2 | HPD | 5C50.1 | |||
| 2-hydroxyglutaric aciduria (D2HGA1) | 1 | 1 | SLC25A1 | 5C50.E1 | |||
| Hyper-β-alaninemia (HBA) | 1 | 1 | Unknown | 5C55.1 | |||
| Not detectable to NBS (amino acids, acylcarnitines and succinylacetone) | |||||||
| Cystinosis (CTNS) | 24 | 24 | CTNS | 5C60.1 | |||
| Ornithine transcarbamylase deficiency (OTC) | 24 | 24 | OTC | 5C50.A3 | |||
| Glycogen storage disease (GSD) | 14 | 1 | 15 | G6PC, AGL, GBE1, PYGM, PHKA2 | 5C51.3 | ||
| Lactic acidemias and other mitochondrial disorders (MIT) | 11 | 2 | 13 | PDX1, SURF1, BCS1L | 5C53 | ||
| Lipoprotein lipase deficiency (LPL) | 7 | 7 | LPL | 5C80.1 | |||
| N-acetyl aspartic aciduria or Canavan disease (CD) | 6 | 6 | ASPA | 5C50.E1 | |||
| Alkaptonuria (AKU) | 2 | 2 | HGD | 5C50.10 | |||
| Glycerol kinase deficiency (GKD) | 2 | 2 | GK | 5C51.1 | |||
| Glucose-galactose malabsorption (GGM) | 1 | 1 | SLC5A1 | 5C61.0 | |||
| Hartnup disease (HND) | 1 | 1 | SLC6A19 | 5C60.Y | |||
| MTHFR deficiency (MTHFRD) | 1 | 1 | MTHFR | 5C63.1 | |||
All the disorders are of autosomal recessive inheritance, except OTC and GSD type IX, which are inherited in an X-linked manner. * International Classification Disorders Classification 11th Revision. ** Initially diagnosed in other medical centers, national or international (mainly USA).
Travel distance from the geographical origin to the reference center and percentage of patients who travel from each Mexican state to attend our institution.
| Mexican State | Approximate Travel Distance to the Reference Center at INP (km) | Number (%) IEiM Patients | |
|---|---|---|---|
| Short travel distance | CDMX | 0 | 177 (19.2) |
| México | 63 | 116 (12.6) | |
| Morelos | 75 | 12 (1.3) | |
| Hidalgo | 91 | 46 (5.0) | |
| Tlaxcala | 133 | 7 (0.8) | |
| Puebla | 147 | 30 (3.2) | |
| Long travel distance | Querétaro | 212 | 32 (3.5) |
| Michoacán | 298 | 34 (3.7) | |
| Veracruz | 308 | 37 (4.0) | |
| Guanajuato | 330 | 49 (5.3) | |
| Guerrero | 368 | 26 (2.9) | |
| San Luis Potosí | 424 | 13 (1.4) | |
| Oaxaca | 474 | 31 (3.4) | |
| Colima | 477 | 3 (0.32) | |
| Aguascalientes | 502 | 14 (1.5) | |
| Jalisco | 536 | 49 (5.3) | |
| Zacatecas | 635 | 10 (1.1) | |
| Chiapas | 705 | 16 (1.7) | |
| Nayarit | 740 | 4 (0.4) | |
| Tabasco | 762 | 68 (7.3) | |
| Durango | 772 | 6 (0.6) | |
| Coahuila | 818 | 2 (0.2) | |
| Campeche | 910 | 3 (0.3) | |
| Nuevo León | 917 | 12 (1.3) | |
| Tamaulipas | 954 | 10 (1.1) | |
| Sinaloa | 1218 | 18 (1.2) | |
| Yucatán | 1323 | 15 (1.6) | |
| Chihuahua | 1559 | 20 (2.1) | |
| Quintana Roo | 1621 | 7 (0.8) | |
| Baja California Sur | 1677 | 5 (0.5) | |
| Sonora | 1890 | 11 (1.2) | |
| Baja California | 2300 | 2 (0.2) | |
| No data | 39 (4.2) |
INP: National Institute of Pediatrics by its abbreviation in Spanish.
Differences in age at arrival, mortality, and access to genetic tests between screened and unscreened patients with inborn errors of intermediary metabolism.
| Total of Patients n = 637 | Screened n = 162 | Unscreened n = 475 |
|---|---|---|
| Median age at arrival to our Center in months (IQR) a | 1.60 (0.93−2.82) **** | 10.10 (1.90−33.37) |
| Min (days) − Max (months) | 1−12.1 | 1−238.43 |
| General mortality | 8/162 (4.94%) **** | 123/475 (25.89%) |
| Adjusted mortality b | 7/44 (15.91%) * | 123/423 (29.08%) |
a IQR: interquartile range. b Without HPA/PKU, MCC, MET, and those diseases that are not detectable by NBS. Differences between screened and unscreened patients: * p = 0.0329, **** p < 0.0001.
Supplementary Materials
The following supporting information can be downloaded at:
References
1. Saudubray, J.-M.; Garcia-Cazorla, À. Inborn errors of metabolism overview: Pathophysiology, manifestations, evaluation, and management. Pediatr. Clin.; 2018; 65, pp. 179-208.
2. Jouvet, P.; Touati, G.; Lesage, F.; Dupic, L.; Tucci, M.; Saudubray, J.M.; Hubert, P. Impact of inborn errors of metabolism on admission and mortality in a pediatric intensive care unit. Eur. J. Pediatr.; 2007; 166, pp. 461-465. [DOI: https://dx.doi.org/10.1007/s00431-006-0265-2] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16941128]
3. Waters, D.; Adeloye, D.; Woolham, D.; Wastnedge, E.; Patel, S.; Rudan, I. Global birth prevalence and mortality from inborn errors of metabolism: A systematic analysis of the evidence. J. Glob. Health; 2018; 8, 021102. [DOI: https://dx.doi.org/10.7189/jogh.08.021102] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30479748]
4. Auger, N.; Nelson, C.; Brousseau, É.; Bilodeau-Bertrand, M.; Dewar, R.; Arbour, L. Extended Risk of Mortality in Children with Inborn Errors of Metabolism: A Longitudinal Cohort Study. J. Pediatr.; 2023; 252, pp. 16-21.e12. [DOI: https://dx.doi.org/10.1016/j.jpeds.2022.08.053]
5. Mathews, C.K.; Van Holde, K. Biochemistry; 2nd ed. Benjamin/Cummings: San Francisco, CA, USA, 1996.
6. García-Cazorla, À.; Saudubray, J.-M. Cellular neurometabolism: A tentative to connect cell biology and metabolism in neurology. J. Inherit. Metab. Dis.; 2018; 41, pp. 1043-1054. [DOI: https://dx.doi.org/10.1007/s10545-018-0226-8]
7. van Karnebeek, C.D.; Stockler, S. Treatable inborn errors of metabolism causing intellectual disability: A systematic literature review. Mol. Genet. Metab.; 2012; 105, pp. 368-381. [DOI: https://dx.doi.org/10.1016/j.ymgme.2011.11.191]
8. Leal, A.F.; Fnu, N.; Benincore-Flórez, E.; Pachón, A.M.H.; Echeverri-Peña, O.Y.; Alméciga-Díaz, C.J.; Tomatsu, S. The landscape of CRISPR/Cas9 for inborn errors of metabolism. Mol. Genet. Metab.; 2022; 138, 106968. [DOI: https://dx.doi.org/10.1016/j.ymgme.2022.106968]
9. Arnold, G.L. Inborn errors of metabolism in the 21st century: Past to present. Ann. Transl. Med.; 2018; 6, 467. [DOI: https://dx.doi.org/10.21037/atm.2018.11.36]
10. Gelb, M.H.; Basheeruddin, K.; Burlina, A.; Chen, H.-J.; Chien, Y.-H.; Dizikes, G.; Dorley, C.; Giugliani, R.; Hietala, A.; Hong, X. Liquid Chromatography–Tandem Mass Spectrometry in Newborn Screening Laboratories. Int. J. Neonatal Screen.; 2022; 8, 62. [DOI: https://dx.doi.org/10.3390/ijns8040062]
11. Shlomi, T.; Cabili, M.N.; Ruppin, E. Predicting metabolic biomarkers of human inborn errors of metabolism. Mol. Syst. Biol.; 2009; 5, 263. [DOI: https://dx.doi.org/10.1038/msb.2009.22]
12. Borrajo, G.J. Newborn screening in Latin America: A brief overview of the state of the art. Am. J. Med. Genet. Part C Semin. Med. Genet.; 2021; 187, pp. 322-328. [DOI: https://dx.doi.org/10.1002/ajmg.c.31899] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33749987]
13. Giugliani, R.; Castillo Taucher, S.; Hafez, S.; Oliveira, J.B.; Rico-Restrepo, M.; Rozenfeld, P.; Zarante, I.; Gonzaga-Jauregui, C. Opportunities and challenges for newborn screening and early diagnosis of rare diseases in Latin America. Front. Genet.; 2022; 13, 3447. [DOI: https://dx.doi.org/10.3389/fgene.2022.1053559] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36568372]
14. Cabello, J.F.; Novoa, F.; Huff, H.V.; Colombo, M. Expanded newborn screening and genomic sequencing in Latin America and the resulting social justice and ethical considerations. Int. J. Neonatal Screen.; 2021; 7, 6. [DOI: https://dx.doi.org/10.3390/ijns7010006] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33494287]
15. García-Flores, E.P.; Herrera-Maldonado, N.; Hinojosa-Trejo, M.A.; Vergara-Vázquez, M.; Halley-Castillo, M.E. Avances y logros del programa de tamiz metabólico neonatal (2012–2018). Acta Pediátrica México; 2018; 39, pp. 57-65. [DOI: https://dx.doi.org/10.18233/APM39No6pp57S-65S1722]
16. Vela-Amieva, M.; Belmont-Martínez, L.; Fernández-Lainez, C.; Ramírez-Frías, C.; Ibarra-González, I. Frecuencia de enfermedades metabólicas congénitas susceptibles de ser identificadas por el tamiz neonatal. Acta Pediátrica México; 2009; 30, pp. 156-162.
17. Fishler, P.K.; Euteneuer, J.C.; Brunelli, L. Ethical Considerations for Equitable Access to Genomic Sequencing for Critically Ill Neonates in the United States. Int. J. Neonatal Screen.; 2022; 8, 22. [DOI: https://dx.doi.org/10.3390/ijns8010022]
18. Stranneheim, H.; Lagerstedt-Robinson, K.; Magnusson, M.; Kvarnung, M.; Nilsson, D.; Lesko, N.; Engvall, M.; Anderlid, B.M.; Arnell, H.; Johansson, C.B. et al. Integration of whole genome sequencing into a healthcare setting: High diagnostic rates across multiple clinical entities in 3219 rare disease patients. Genome Med.; 2021; 13, 40. [DOI: https://dx.doi.org/10.1186/s13073-021-00855-5]
19. Collins, F.S.; Doudna, J.A.; Lander, E.S.; Rotimi, C.N. Human Molecular Genetics and Genomics—Important Advances and Exciting Possibilities. N. Engl. J. Med.; 2021; 384, pp. 1-4. [DOI: https://dx.doi.org/10.1056/NEJMp2030694]
20. Velázquez-Aragón, J.; Alcántara-Ortigoza, M.; Vela-Amieva, M.; Monroy, S.; Martínez-Cruz, V.; Todd-Quiñones, C.; González-del Angel, A. Low allelic heterogeneity in a sample of Mexican patients with classical galactosaemia. J. Inherit. Metab. Dis. Off. J. Soc. Study Inborn Errors Metab.; 2008; 31, pp. 333-337. [DOI: https://dx.doi.org/10.1007/s10545-008-0905-y]
21. Méndez, S.T.; Vela-Amieva, M.; Velázquez-Arellano, A.; Ibarra, I.; Flores, M.E. Análisis de mutaciones en el gen de la metilmalonilCoA mutasa en diez pacientes mexicanos con acidemia metilmalónica aislada. Rev. Investig. Clin.; 2012; 64, pp. 255-261.
22. Alcantara-Ortigoza, M.A.; Belmont-Martinez, L.; Vela-Amieva, M.; González-Del Angel, A. Analysis of the CTNS gene in nephropathic cystinosis Mexican patients: Report of four novel mutations and identification of a false positive 57-kb deletion genotype with LDM-2/exon 4 multiplex PCR assay. Genet. Test.; 2008; 12, pp. 409-414. [DOI: https://dx.doi.org/10.1089/gte.2008.0014]
23. Ibarra-González, I.; Fernández-Lainez, C.; Belmont-Martínez, L.; Guillén-López, S.; Monroy-Santoyo, S.; Vela-Amieva, M. Caracterización de errores innatos del metabolismo intermediario en pacientes mexicanos. An. Pediatría; 2014; 80, pp. 310-316. [DOI: https://dx.doi.org/10.1016/j.anpedi.2013.09.003]
24. Ibarra-González, I.; Ridaura-Sanz, C.; Fernández-Lainez, C.; Guillén-López, S.; Belmont-Martínez, L.; Vela-Amieva, M. Hepatorenal Tyrosinemia in Mexico: A Call to Action. Adv. Exp. Med. Biol.; 2017; 959, pp. 147-156. [DOI: https://dx.doi.org/10.1007/978-3-319-55780-9_14] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28755193]
25. Campos-Garcia, F.J.; Chacon-Camacho, O.F.; Contreras-Capetillo, S.; Cruz-Aguilar, M.; Medina-Escobedo, C.E.; Moreno-Graciano, C.M.; Rodas, A.; Herrera-Perez, L.D.A.; Zenteno, J.C. Characterization of novel GCDH pathogenic variants causing glutaric aciduria type 1 in the southeast of Mexico. Mol. Genet. Metab. Rep.; 2019; 21, 100533. [DOI: https://dx.doi.org/10.1016/j.ymgmr.2019.100533] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31788423]
26. Ibarra-González, I.; Fernández-Lainez, C.; Guillén-López, S.; López-Mejía, L.; Belmont-Matínez, L.; Sokolsky, T.D.; Amin, V.R.; Kitchener, R.L.; Vela-Amieva, M.; Naylor, E.W. Molecular analysis using targeted next generation DNA sequencing and clinical spectrum of Mexican patients with isovaleric acidemia. Clin. Chim. Acta; 2020; 501, pp. 216-221. [DOI: https://dx.doi.org/10.1016/j.cca.2019.10.041] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31707166]
27. Vela-Amieva, M.; Alcántara-Ortigoza, M.A.; Ibarra-González, I.; González-del Angel, A.; Fernández-Hernández, L.; Guillén-López, S.; López-Mejía, L.; Carrillo-Nieto, R.I.; Belmont-Martínez, L.; Fernández-Lainez, C. An Updated PAH Mutational Spectrum of Phenylketonuria in Mexican Patients Attending a Single Center: Biochemical, Clinical-Genotyping Correlations. Genes; 2021; 12, 1676. [DOI: https://dx.doi.org/10.3390/genes12111676]
28. Vela-Amieva, M.; Alcántara-Ortigoza, M.A.; Ibarra-González, I.; González-Del Angel, A.; Fernández-Hernández, L.; Guillén-López, S.; López-Mejía, L.; Carrillo-Nieto, R.I.; Fiesco-Roa, M.O.; Fernández-Lainez, C. Genotypic spectrum underlying tetrahydrobiopterin metabolism defects: Experience in a single Mexican reference center. Front. Genet.; 2022; 13, 993612. [DOI: https://dx.doi.org/10.3389/fgene.2022.993612]
29. Ibarra-González, I.F.-L.C.; Guillén-López, S.; López-Mejía, L.; Belmont-Martínez, L.; Nieto-Carrillo, R.I.; Vela-Amieva, M. Importance of Studying Older Siblings of Patients Identified by Newborn Screening: A Single-Center Experience in Mexico. J. Inborn Errors Metab. Screen.; 2021; 9, pp. 1-7. [DOI: https://dx.doi.org/10.1590/2326-4594-jiems-2021-0001]
30. Sontag, M.K.; Sarkar, D.; Comeau, A.M.; Hassell, K.; Botto, L.D.; Parad, R.; Rose, S.R.; Wintergerst, K.A.; Smith-Whitley, K.; Singh, S. et al. Case Definitions for Conditions Identified by Newborn Screening Public Health Surveillance. Int. J. Neonatal Screen.; 2018; 4, 16. [DOI: https://dx.doi.org/10.3390/ijns4020016]
31. Watson, M.S.; Mann, M.Y.; Lloyd-Puryear, M.A.; Rinaldo, P.; Howell, R.R. American College of Medical Genetics Newborn screening: Toward a uniform screening panel and system—Executive summary. Pediatrics; 2006; 117, pp. S296-S307. [DOI: https://dx.doi.org/10.1542/peds.2005-2633I]
32. Sontag, M.K.; Miller, J.I.; McKasson, S.; Sheller, R.; Edelman, S.; Yusuf, C.; Singh, S.; Sarkar, D.; Bocchini, J.; Scott, J. et al. Newborn screening timeliness quality improvement initiative: Impact of national recommendations and data repository. PLoS ONE; 2020; 15, e0231050. [DOI: https://dx.doi.org/10.1371/journal.pone.0231050] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32240266]
33. Chen, H.F.; Rose, A.M.; Waisbren, S.; Ahmad, A.; Prosser, L.A. Newborn Screening and Treatment of Phenylketonuria: Projected Health Outcomes and Cost-Effectiveness. Children; 2021; 8, 381. [DOI: https://dx.doi.org/10.3390/children8050381] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34065950]
34. Grünert, S.C.; Stucki, M.; Morscher, R.J.; Suormala, T.; Bürer, C.; Burda, P.; Christensen, E.; Ficicioglu, C.; Herwig, J.; Kölker, S. 3-methylcrotonyl-CoA carboxylase deficiency: Clinical, biochemical, enzymatic and molecular studies in 88 individuals. Orphanet J. Rare Dis.; 2012; 7, 31. [DOI: https://dx.doi.org/10.1186/1750-1172-7-31] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22642865]
35. Zhang, R.; Qiang, R.; Song, C.; Ma, X.; Zhang, Y.; Li, F.; Wang, R.; Yu, W.; Feng, M.; Yang, L. et al. Spectrum analysis of inborn errors of metabolism for expanded newborn screening in a northwestern Chinese population. Sci. Rep.; 2021; 11, 2699. [DOI: https://dx.doi.org/10.1038/s41598-021-81897-y] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33514801]
36. Ramoser, G.; Caferri, F.; Radlinger, B.; Brunner-Krainz, M.; Herbst, S.; Huemer, M.; Hufgard-Leitner, M.; Kircher, S.G.; Konstantopoulou, V.; Löscher, W. et al. 100 years of inherited metabolic disorders in Austria-A national registry of minimal birth prevalence, diagnosis, and clinical outcome of inborn errors of metabolism in Austria between 1921 and 2021. J. Inherit. Metab. Dis.; 2022; 45, pp. 144-156. [DOI: https://dx.doi.org/10.1002/jimd.12442] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34595757]
37. Vela-Amieva, M.; Abreu-Gonzalez, M.; Gonzalez-del Angel, A.; Ibarra-Gonzalez, I.; Fernandez-Lainez, C.; Barrientos-Rios, R.; Monroy-Santoyo, S.; Guillén-López, S.; Alcántara-Ortigoza, M. Phenylalanine hydroxylase deficiency in Mexico: Genotype–phenotype correlations, BH4 responsiveness and evidence of a founder effect. Clin. Genet.; 2015; 88, pp. 62-67. [DOI: https://dx.doi.org/10.1111/cge.12444] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24941924]
38. Vela-Amieva, M.; Ibarra-González, I.; del Alba Herrera-Pérez, L.; Caamal-Parra, G.; Belmont-Martínez, L.; García-Flores, E.P. Epidemiología de la fenilcetonuria obtenida mediante tamiz neonatal. Acta Pediátrica México; 2019; 39, pp. 25-34. [DOI: https://dx.doi.org/10.18233/APM39No6pp25S-34S1719]
39. Wilcken, B. Fatty acid oxidation disorders: Outcome and long-term prognosis. J. Inherit. Metab. Dis.; 2010; 33, pp. 501-506. [DOI: https://dx.doi.org/10.1007/s10545-009-9001-1]
40. Lüders, A.; Blankenstein, O.; Brockow, I.; Ensenauer, R.; Lindner, M.; Schulze, A.; Nennstiel, U. Neonatal screening for congenital metabolic and endocrine disorders: Results from Germany for the years 2006–2018. Dtsch. Ärzteblatt Int.; 2021; 118, 101.
41. Feuchtbaum, L.; Carter, J.; Dowray, S.; Currier, R.J.; Lorey, F. Birth prevalence of disorders detectable through newborn screening by race/ethnicity. Genet. Med.; 2012; 14, pp. 937-945. [DOI: https://dx.doi.org/10.1038/gim.2012.76]
42. Iafolla, A.K.; Thompson Jr, R.J.; Roe, C.R. Medium–chain acyl-coenzyme A dehydrogenase deficiency: Clinical course in 120 affected children. J. Pediatr.; 1994; 124, pp. 409-415. [DOI: https://dx.doi.org/10.1016/S0022-3476(94)70363-9] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8120710]
43. Nennstiel-Ratzel, U.; Arenz, S.; Maier, E.M.; Knerr, I.; Baumkötter, J.; Röschinger, W.; Liebl, B.; Hadorn, H.-B.; Roscher, A.A.; von Kries, R. Reduced incidence of severe metabolic crisis or death in children with medium chain acyl-CoA dehydrogenase deficiency homozygous for c. 985A> G identified by neonatal screening. Mol. Genet. Metab.; 2005; 85, pp. 157-159. [DOI: https://dx.doi.org/10.1016/j.ymgme.2004.12.010] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15896661]
44. Gómez-Dantés, O.; Flamand, L.; Cerecero-García, D.; Morales-Vazquez, M.; Serván-Mori, E. Origin, impacts and potential solutions to the fragmentation of the Mexican health system: A consultation to key actors. Health Res. Policy Syst.; 2023; 21, 80. [DOI: https://dx.doi.org/10.1186/s12961-023-01025-2]
45. Yusuf, C.; Sontag, M.K.; Miller, J.; Kellar-Guenther, Y.; McKasson, S.; Shone, S.; Singh, S.; Ojodu, J. Development of national newborn screening quality indicators in the United States. Int. J. Neonatal Screen.; 2019; 5, 34. [DOI: https://dx.doi.org/10.3390/ijns5030034] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33072993]
46. Pandor, A.; Eastham, J.; Beverley, C.; Chilcott, J.; Paisley, S. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: A systematic review. Health Technol Assess; 2004; 8, pp. 1-121. [DOI: https://dx.doi.org/10.3310/hta8120]
47. Feuchtbaum, L.; Cunningham, G. Economic evaluation of tandem mass spectrometry screening in California. Pediatrics; 2006; 117, pp. S280-S286. [DOI: https://dx.doi.org/10.1542/peds.2005-2633G]
48. Bittles, A.H.; Black, M.L. Consanguinity, human evolution, and complex diseases. Proc. Natl. Acad. Sci. USA; 2010; 107, pp. 1779-1786. [DOI: https://dx.doi.org/10.1073/pnas.0906079106]
49. Sass, J.; Hofmann, M.; Skladal, D.; Mayatepek, E.; Schwahn, B.; Sperl, W. Propionic acidemia revisited: A workshop report. Clin. Pediatr.; 2004; 43, pp. 837-843. [DOI: https://dx.doi.org/10.1177/000992280404300908]
50. Yap, S.; Vara, R.; Morais, A. Post-transplantation Outcomes in Patients with PA or MMA: A Review of the Literature. Adv. Ther.; 2020; 37, pp. 1866-1896. [DOI: https://dx.doi.org/10.1007/s12325-020-01305-1]
51. Barshes, N.R.; Vanatta, J.M.; Patel, A.J.; Carter, B.A.; O’Mahony, C.A.; Karpen, S.J.; Goss, J.A. Evaluation and management of patients with propionic acidemia undergoing liver transplantation: A comprehensive review. Pediatr. Transpl.; 2006; 10, pp. 773-781. [DOI: https://dx.doi.org/10.1111/j.1399-3046.2006.00569.x]
52. Forny, P.; Hörster, F.; Ballhausen, D.; Chakrapani, A.; Chapman, K.A.; Dionisi-Vici, C.; Dixon, M.; Grünert, S.C.; Grunewald, S.; Haliloglu, G. et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: First revision. J. Inherit. Metab. Dis.; 2021; 44, pp. 566-592. [DOI: https://dx.doi.org/10.1002/jimd.12370]
53. Frazier, D.M.; Allgeier, C.; Homer, C.; Marriage, B.J.; Ogata, B.; Rohr, F.; Splett, P.L.; Stembridge, A.; Singh, R.H. Nutrition management guideline for maple syrup urine disease: An evidence- and consensus-based approach. Mol. Genet. Metab.; 2014; 112, pp. 210-217. [DOI: https://dx.doi.org/10.1016/j.ymgme.2014.05.006]
54. Häberle, J.; Burlina, A.; Chakrapani, A.; Dixon, M.; Karall, D.; Lindner, M.; Mandel, H.; Martinelli, D.; Pintos-Morell, G.; Santer, R. et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. J. Inherit. Metab. Dis.; 2019; 42, pp. 1192-1230. [DOI: https://dx.doi.org/10.1002/jimd.12100] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30982989]
55. Vela-Amieva, M.; Ibarra-González, I.; Monroy-Santoyo, S.; Fernández-Lainez, C.; Guillén López, S.; Belmont Martínez, L.; Hernández Montiel, A.; González del Angel, A.; Ruiz-García, M.; Sánchez-Pérez, M.C. et al. Modelo de atención inicial de la fenilcetonuria y otras hiperfenilalaninemias en el Instituto Nacional de Pediatría. Acta Pediátrica México; 2010; 6, 297.
56. Vela-Amieva, M.; Ibarra-González, I.; Fernández-Lainez, C.; Belmont-Martínez, L. Fundamentos teórico-prácticos para la toma correcta de la muestra de sangre del talón para el tamiz neonatal. Acta Pediátrica México; 2012; 33, pp. 273-278. [DOI: https://dx.doi.org/10.18233/APM33No6pp273-278]
57. López, S.G.; López-Mejía, L.; Carrillo-Nieto, R.I.; Martínez, L.B.; González, I.I.; Fernández-Lainez, C.; Vela-Amieva, M. Seguimiento bioquímico y dosis de medicamentos de EIM del metabolismo intermedio. Acta Pediátrica México; 2023; 44, pp. 75-82. [DOI: https://dx.doi.org/10.18233/APM44No1pp75-822573]
58. Sebastião, F.M.; Michelin-Tirelli, K.; Bender, F.; Lopes, F.F.; Moraes, I.; Kubaski, F.; Giugliani, R.; Burin, M. COVID-19 impact on the diagnosis of Inborn Errors of Metabolism: Data from a reference center in Brazil. Genet. Mol. Biol.; 2021; 45, e20210253. [DOI: https://dx.doi.org/10.1590/1678-4685-gmb-2021-0253] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34927665]
59. Özalp Akın, E.; Eminoğlu, F.T.; Doğulu, N.; Koç Yekeduz, M.; Öncül, U.; Akpınar, F.; Hayran, G. Unmet Needs of Children with Inherited Metabolic Disorders in the COVID-19 Pandemic. Turk. Arch. Pediatr.; 2022; 57, pp. 335-341. [DOI: https://dx.doi.org/10.5152/TurkArchPediatr.2022.21367]
60. Gray, J.M.; Patnick, J.; Blanks, R. Maximising benefit and minimising harm of screening. BMJ; 2008; 336, pp. 480-483. [DOI: https://dx.doi.org/10.1136/bmj.39470.643218.94]
61. Odenwald, B.; Brockow, I.; Hanauer, M.; Lüders, A.; Nennstiel, U. Is Our Newborn Screening Working Well? A Literature Review of Quality Requirements for Newborn Blood Spot Screening (NBS) Infrastructure and Procedures. Int. J. Neonatal Screen.; 2023; 9, 35. [DOI: https://dx.doi.org/10.3390/ijns9030035]
62. Maier, E.M.; Mütze, U.; Janzen, N.; Steuerwald, U.; Nennstiel, U.; Odenwald, B.; Schuhmann, E.; Lotz-Havla, A.S.; Weiss, K.J.; Hammersen, J. Collaborative evaluation study on 18 candidate diseases for newborn screening in 1.77 million samples. J. Inherit. Metab. Dis.; 2023; Online ahead of print [DOI: https://dx.doi.org/10.1002/jimd.12671] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/37603033]
63. Feuchtbaum, L.; Yang, J.; Currier, R. Follow-up status during the first 5 years of life for metabolic disorders on the federal Recommended Uniform Screening Panel. Genet. Med.; 2018; 20, pp. 831-839. [DOI: https://dx.doi.org/10.1038/gim.2017.199] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29215646]
64. Wilcken, B. 3-Methylcrotonyl-CoA carboxylase deficiency: To screen or not to screen?. J. Inherit. Metab. Dis.; 2016; 39, pp. 171-172. [DOI: https://dx.doi.org/10.1007/s10545-015-9906-9] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26660660]
65. Chadwick, S.; Fitzgerald, K.; Weiss, B.; Ficicioglu, C. Thirteen patients with MAT1A mutations detected through newborn screening: 13 years’ experience. JIMD Rep.; 2014; 14, pp. 71-76.
66. Woerner, A.C.; Gallagher, R.C.; Vockley, J.; Adhikari, A.N. The Use of Whole Genome and Exome Sequencing for Newborn Screening: Challenges and Opportunities for Population Health. Front. Pediatr.; 2021; 9, 663752. [DOI: https://dx.doi.org/10.3389/fped.2021.663752]
67. Petrikin, J.E.; Cakici, J.A.; Clark, M.M.; Willig, L.K.; Sweeney, N.M.; Farrow, E.G.; Saunders, C.J.; Thiffault, I.; Miller, N.A.; Zellmer, L. et al. The NSIGHT1-randomized controlled trial: Rapid whole-genome sequencing for accelerated etiologic diagnosis in critically ill infants. NPJ Genom. Med.; 2018; 3, 6. [DOI: https://dx.doi.org/10.1038/s41525-018-0045-8]
68. Peterson, B.; Hernandez, E.J.; Hobbs, C.; Malone Jenkins, S.; Moore, B.; Rosales, E.; Zoucha, S.; Sanford, E.; Bainbridge, M.N.; Frise, E. et al. Automated prioritization of sick newborns for whole genome sequencing using clinical natural language processing and machine learning. Genome Med.; 2023; 15, 18. [DOI: https://dx.doi.org/10.1186/s13073-023-01166-7]
69. Hörster, F.; Baumgartner, M.R.; Viardot, C.; Suormala, T.; Burgard, P.; Fowler, B.; Hoffmann, G.F.; Garbade, S.F.; Kölker, S.; Baumgartner, E. Long-term outcome in methylmalonic acidurias is influenced by the underlying defect (mut0, mut−, cblA, cblB). Pediatr. Res.; 2007; 62, pp. 225-230. [DOI: https://dx.doi.org/10.1203/PDR.0b013e3180a0325f]
70. Hörster, F.; Tuncel, A.T.; Gleich, F.; Plessl, T.; Froese, S.D.; Garbade, S.F.; Kölker, S.; Baumgartner, M.R. Additional Contributors from E-IMD. Delineating the clinical spectrum of isolated methylmalonic acidurias: cblA and mut. J. Inherit. Metab. Dis.; 2021; 44, pp. 193-214. [DOI: https://dx.doi.org/10.1002/jimd.12297]
71. Chen, T.; Fan, C.; Huang, Y.; Feng, J.; Zhang, Y.; Miao, J.; Wang, X.; Li, Y.; Huang, C.; Jin, W. Genomic Sequencing as a First-Tier Screening Test and Outcomes of Newborn Screening. JAMA Netw. Open; 2023; 6, e2331162. [DOI: https://dx.doi.org/10.1001/jamanetworkopen.2023.31162]
72. Lalonde, E.; Rentas, S.; Lin, F.; Dulik, M.C.; Skraban, C.M.; Spinner, N.B. Genomic Diagnosis for Pediatric Disorders: Revolution and Evolution. Front. Pediatr.; 2020; 8, 373. [DOI: https://dx.doi.org/10.3389/fped.2020.00373] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32733828]
73. Yubero, D.; Brandi, N.; Ormazabal, A.; Garcia-Cazorla, À.; Pérez-Dueñas, B.; Campistol, J.; Ribes, A.; Palau, F.; Artuch, R.; Armstrong, J. Targeted Next Generation Sequencing in Patients with Inborn Errors of Metabolism. PLoS ONE; 2016; 11, e0156359. [DOI: https://dx.doi.org/10.1371/journal.pone.0156359] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27243974]
74. Ghosh, A.; Schlecht, H.; Heptinstall, L.E.; Bassett, J.K.; Cartwright, E.; Bhaskar, S.S.; Urquhart, J.; Broomfield, A.; Morris, A.A.; Jameson, E. et al. Diagnosing childhood-onset inborn errors of metabolism by next-generation sequencing. Arch. Dis. Child.; 2017; 102, pp. 1019-1029. [DOI: https://dx.doi.org/10.1136/archdischild-2017-312738] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28468868]
75. Soriano-Sexto, A.; Gallego, D.; Leal, F.; Castejón-Fernández, N.; Navarrete, R.; Alcaide, P.; Couce, M.L.; Martín-Hernández, E.; Quijada-Fraile, P.; Peña-Quintana, L. et al. Identification of Clinical Variants beyond the Exome in Inborn Errors of Metabolism. Int. J. Mol. Sci.; 2022; 23, 12850. [DOI: https://dx.doi.org/10.3390/ijms232112850]
76. Ibarra-González, I.; Fernández-Lainez, C.; Alcántara-Ortigoza, M.A.; González-Del Angel, A.; Fernández-Henández, L.; Guillén-López, S.; Belmont-Martínez, L.; López-Mejía, L.; Varela-Fascinetto, G.; Vela-Amieva, M. Mutational spectrum of Mexican patients with tyrosinemia type 1: In silico modeling and predicted pathogenic effect of a novel missense FAH variant. Mol. Genet. Genom. Med.; 2019; 7, e937. [DOI: https://dx.doi.org/10.1002/mgg3.937]
77. Taruscio, D.; Salvatore, M.; Lumaka, A.; Carta, C.; Cellai, L.L.; Ferrari, G.; Sciascia, S.; Groft, S.; Alanay, Y.; Azam, M. Undiagnosed diseases: Needs and opportunities in 20 countries participating in the Undiagnosed Diseases Network International. Front. Public Health; 2023; 11, 1079601. [DOI: https://dx.doi.org/10.3389/fpubh.2023.1079601]
78. Brasil, S.; Leal, F.; Vega, A.; Navarrete, R.; Ecay, M.J.; Desviat, L.R.; Riera, C.; Padilla, N.; de la Cruz, X.; Couce, M.L. et al. Improving the diagnosis of cobalamin and related defects by genomic analysis, plus functional and structural assessment of novel variants. Orphanet J. Rare Dis.; 2018; 13, 125. [DOI: https://dx.doi.org/10.1186/s13023-018-0862-y]
79. Pupavac, M.; Tian, X.; Chu, J.; Wang, G.; Feng, Y.; Chen, S.; Fenter, R.; Zhang, V.W.; Wang, J.; Watkins, D. et al. Added value of next generation gene panel analysis for patients with elevated methylmalonic acid and no clinical diagnosis following functional studies of vitamin B12 metabolism. Mol. Genet. Metab.; 2016; 117, pp. 363-368. [DOI: https://dx.doi.org/10.1016/j.ymgme.2016.01.008]
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Fernández-Lainez, Cynthia 2
; Vela-Amieva, Marcela 2 ; Guillén-López, Sara 2 ; Belmont-Martínez, Leticia 2 ; López-Mejía, Lizbeth 2
; Carrillo-Nieto, Rosa Itzel 2
; Guillén-Zaragoza, Nidia Alejandra 3 1 Laboratorio de Errores Innatos del Metabolismo y Tamiz, Instituto Nacional de Pediatría, Secretaría de Salud, Ciudad de México 04530, Mexico; Unidad de Genética de la Nutrición, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico
2 Laboratorio de Errores Innatos del Metabolismo y Tamiz, Instituto Nacional de Pediatría, Secretaría de Salud, Ciudad de México 04530, Mexico
3 Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico